Suchergebnisse - "Zhou, Jianying"

PubPharm (18)

1

Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2024

von Drilon, A. | Camidge, D. | Lin, J. | +131

2

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation : A pooled analysis of two clinical studies

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Yang, S. | Wu, S. | Zhao, Y. | +54

3

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

enthalten in: BMC medicine | 2023

von Shi, Y. | Zhou, J. | Zhao, Y. | +13

4

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

enthalten in: Cancer discovery | 2022

von Wang, M. | Yang, J. | Mitchell, P. | +22

5

A novel stilbene derivative (GMQ3) suppressed proliferation and induced apoptosis in lung cancer via the p38-MAPK/SIRT1 pathway

enthalten in: Biochemical pharmacology | 2021

von Xia, M. | Cao, H. | Zheng, J. | +5

6

Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib : Results from ASCEND-6

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2020

von Wu, Y. | Shi, Y. | Tan, D. | +11

7

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC : A Multicenter, Open-label, Phase 1 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Yang, J. | Camidge, D. | Yang, C. | +26

8

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

enthalten in: The New England journal of medicine | 2020

von Shaw, A. | Bauer, T. | de Marinis, F. | +112

CommentIn: Nat Rev Clin Oncol. 2021 Jan;18(1):6. - PMID 33262501

9

Honokiol induces apoptosis of lung squamous cell carcinoma by targeting FGF2-FGFR1 autocrine loop

enthalten in: Cancer medicine | 2018

von Cen, M. | Yao, Y. | Cui, L. | +5

10

Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2018

von Si, X. | Zhang, L. | Wang, H. | +19